MENA Post-Market Surveillance & Vigilance: SFDA, EDE & Regional Requirements (2026)
Complete guide to post-market surveillance and vigilance requirements for medical devices across MENA — SFDA MDS-REQ11 (2-day/10-day/30-day reporting, change notifications, 90-day renewal), UAE EDE biennial PSUR for high-risk devices, Turkey TITCK 6-month shortage notification, Israel IRH periodic post-marketing reports, and Egypt EDA vigilance obligations.
Post-Market Surveillance Is the New Regulatory Battleground in MENA
Across the Middle East and North Africa, regulatory authorities are dramatically intensifying their post-market surveillance (PMS) requirements for medical devices. In 2026, the shift is unmistakable: Saudi Arabia's SFDA enforces detailed vigilance timelines under MDS-REQ 11, the UAE's Emirates Drug Establishment (EDE) mandates biennial safety reports for high-risk devices, Turkey's TITCK requires six months' advance notice of supply interruptions, and Israel's AMAR demands periodic post-marketing reports through the Israel Registration Holder (IRH).
For manufacturers accustomed to treating PMS as a post-registration formality, the MENA region now requires robust, proactive systems with country-specific reporting timelines, complaint handling procedures, and periodic safety update mechanisms. Failure to comply risks not only regulatory penalties but also product withdrawal, import holds, and loss of marketing authorization.
This guide covers the complete PMS and vigilance landscape across the region's five largest medical device markets.
Saudi Arabia: SFDA MDS-REQ 11 — The Region's Most Detailed Framework
Regulatory Foundation
The Saudi Food and Drug Authority (SFDA) enforces post-market surveillance through MDS-REQ 11 ("Requirements for Post-Market Surveillance of Medical Devices"), which is part of a comprehensive regulatory framework including:
| Requirement | Scope |
|---|---|
| MDS-REQ 1 | Medical Device Marketing Authorization (MDMA) |
| MDS-REQ 5 | Shipments Clearance and Importation |
| MDS-REQ 7 | Unique Device Identification (UDI) |
| MDS-REQ 10 | Inspection and Quality Management System |
| MDS-REQ 11 | Post-Market Surveillance |
| MDS-REQ 12 | Transportation and Storage |
Adverse Event Reporting Timelines
Saudi Arabia's adverse event reporting follows a risk-based tiered system:
| Event Severity | Initial Reporting Timeline |
|---|---|
| Severe public health threat (imminent risk of death) | 2 calendar days |
| Death or unanticipated serious injury | 10 calendar days |
| All other reportable incidents | 30 calendar days |
Investigation and Final Report Timelines
Once an adverse event is reported, the investigation must be concluded and the final report submitted to the National Center for Medical Device Reporting (NCMDR) within:
| Investigation Type | Timeline |
|---|---|
| Events not requiring testing or technical evaluation | 15 days |
| Events requiring testing inside KSA | 30 days |
| Events requiring testing outside KSA | 60 days |
Reporting Channels
Manufacturers and authorized representatives submit adverse event and complaint information through:
- NCMDR (National Center for Medical Device Reporting)
- Saudi Vigilance system
- Call Center (19999)
Field Safety Corrective Actions (FSCA)
The FSCA process follows a structured five-stage model:
Stage 1 — Reporting: The manufacturer or authorized representative reports FSCA affecting KSA to NCMDR within 2 days of issuing the FSCA letter, attaching the FSCA letter with required information per Annex 1.
Stage 2 — SFDA Response: If SFDA issues a safety alert or inquiry, the manufacturer must respond within 5 days through NCMDR email (ncmdr.md@sfda.gov.sa).
Stage 3 — User Notification: Importers, distributors, healthcare providers, and users must be notified within 5 days of reporting to NCMDR. Notification methods include email, national address, phone call, or visiting affected customers. Documented proof of notification is required (signed acknowledgment forms).
Stage 4 — Corrective Action Implementation: Execute the corrective action plan.
Stage 5 — Closure: Submit final documentation for case closure.
Change Notification Requirements
Changes to registered medical devices are classified as significant or non-significant:
| Change Type | Requirement | Timeline |
|---|---|---|
| Significant changes | Prior approval from SFDA | Report within 10 days of change |
| Non-significant changes | Notification only (no approval needed) | Report within 30 days of change |
For non-significant changes, the manufacturer sends an email using the certificate number as subject, containing a short description including device name, MDMA number, model number, and national listing number. Complete information must be submitted within 90 days of the change.
MDMA Renewal
Marketing authorization renewals must be submitted at least 90 days before expiry through the electronic system. Updated documents must be submitted as necessary.
Periodic Safety Update Reports (PSURs)
For higher-risk devices (Class C and D), manufacturers must submit Periodic Safety Update Reports (PSURs) to SFDA summarizing safety and performance data on a regular basis. PSURs must include:
- Results and conclusions from PMS data analysis
- Update on benefit-risk determination
- Main findings of post-market clinical follow-up
- Sales volume and estimated user population
- Usage frequency of the device
- Description of preventive and corrective actions taken
Documentation Retention
All PMS records must be retained for at least 10 years after the last device has been placed on the market, or 15 years for implantable devices.
2026 Enforcement Statistics
According to SFDA data, in 2024 the authority processed 393 safety alerts resulting in 15 decisions, with 290 corrections and 103 removals. Risk classification showed 318 high-risk decisions, 15 medium-risk, and quantities of medical devices affected reaching over 26.8 million units. The closure rate was 58%, with 42% still under progress.
United Arab Emirates: EDE Post-Market Requirements
Regulatory Authority
The Emirates Drug Establishment (EDE) assumed full responsibility for medical device post-market surveillance in 2026, consolidating functions previously managed by MOHAP. EDE enforces PMS obligations through its digital portal at www.ede.gov.ae.
Adverse Event Reporting Timelines
| Event Type | Reporting Timeline |
|---|---|
| Public health concerns | 48 hours |
| Serious injuries and deaths | 10 days |
| All other incidents | 30 days |
Periodic Safety Update Reports (PSURs)
High-risk medical devices (Class III and IV) are required to submit Periodic Safety Update Reports (PSURs) every 2 years (biennially). PSUR documentation must include:
- Sales records
- Log of consumer feedback
- Documentation of incidents
- History of changes
- Product performance evaluation data
- Evidence of corrective and preventive actions
PSURs are submitted in accordance with the UAE's Good Vigilance Practice (GVP) guidelines. The UAE MOHAP GVP Guidelines (Version 1.3) specify:
- Within 70 calendar days of the data lock point for PSURs covering intervals up to 12 months
- Within 90 calendar days for PSURs covering intervals exceeding 12 months
- PSUR frequencies should be harmonized with the EURD (European Reference Dates) calendar
Complaint Handling System Requirements
Manufacturers must maintain a formal complaint handling procedure that includes:
- Recording and documentation of all complaints
- Technical investigation of device issues
- Root cause identification
- Implementation of corrective actions
- Evaluation to determine whether regulatory reporting is required
Registration Renewal and PMS
UAE medical device registrations are valid for 5 years. Renewal should start 3–6 months before expiry. The renewal process requires:
- Post-market surveillance / monitoring reports (as applicable)
- Updated certificates and conformity documentation
- Physical samples when required (usually 3 samples with Certificate of Analysis)
- Product brochures and packaging graphics
- Company affirmation of compliance with regulatory technical specifications
Renewal Fees:
- Application fee: 100 AED
- Renewal of medical device registration: 2,500 AED
- Higher-risk devices may incur fees around 10,000 AED plus application fee
Post-Approval Changes
| Change Type | Requirement |
|---|---|
| Minor changes | Notification only |
| Significant changes | New approval required |
Abu Dhabi DOH Post-Marketing Surveillance
The Department of Health – Abu Dhabi (DOH) operates a dedicated Post-Marketing Surveillance Program with a 5-year action plan addressing:
- Risk management framework for non-registered medications
- Periodic laboratory testing to ensure quality of medicines distributed in Abu Dhabi
- Assessment of generic efficacy
- Focus on highly consumed products (chronic medications, antibiotics)
- Critical drugs monitoring (antidotes, cardiac arrest, antiplatelet therapies)
- Market complaints and quality issues
DOH issues circulars to healthcare providers forwarding EDE field safety alerts, requiring:
- Follow-up on affected devices listed in manufacturer safety notices
- Reporting of adverse effects to the Pharmacovigilance program via email (PVE@doh.gov.ae)
Turkey: TITCK Vigilance and Supply Chain Requirements
Regulatory Framework
Turkey's Turkish Pharmaceuticals and Medical Devices Agency (TITCK) enforces medical device post-market requirements through regulations aligned with the EU MDR and IVDR framework. Turkey's EU candidacy means its regulatory framework closely mirrors EU requirements, including PMS obligations.
Medical Device Shortage Notification
TITCK has introduced a critical requirement for medical device supply interruption/shortage notifications:
- Manufacturers must notify TITCK at least 6 months before the anticipated start of a shortage or discontinuation
- This applies whenever the event could cause serious harm, or a credible risk of serious harm, to patients or public health in Turkey or in EU Member States
- Only custom-made devices are exempt
- Six-month lead time allows authorities and clinical stakeholders to organize contingency measures: stock redistribution, accelerated import licensing, substitution with equivalent products
For manufacturers established in Turkey: Submit notification directly to TITCK through the designated department (Department of Medical Device Market Surveillance: tibbicihaz.pgd@titck.gov.tr).
For EU-based manufacturers: Notify the competent authority of the EU Member State under MDR Article 59 or IVDR Article 56. TITCK waives the Turkish notice when the shortage affects both EU and Turkey equally. However, if the disruption is confined to Turkey (e.g., local reimbursement changes, customs delays, distributor insolvency), the Turkish importer must submit notification within the same six-month window.
Pharmacovigilance and Adverse Event Reporting
Turkey operates the Turkish Pharmacovigilance Center (TUFAM) under the Ministry of Health:
- Adverse effects or suspected adverse effects from medical devices must be reported
- Marketing authorization holders, healthcare professionals, and healthcare institutions all have reporting obligations
- Patient data and adverse effect notifications are confidential
- Reporting requirements follow EU MDR-aligned timelines
Product Exclusion Clarifications (2026)
TITCK published a 2026 update clarifying which products do not fall within medical device scope and therefore should not be registered in the ÜTS (National Product Tracking System):
- Hospital furniture and textiles without specific medical function
- General-purpose laboratory equipment not marketed for medical use
- Products with purely cosmetic or general consumer purposes
Misclassification can lead to regulatory audits and non-compliance penalties.
Department Contacts for PMS
| Department | Responsibility | Contact |
|---|---|---|
| Department of EU Legislation | EU-aligned MDR/IVDR regulations | md.reg@titck.gov.tr |
| Department of Clinical Engineering | Clinical device management | kmb@titck.gov.tr |
| Department of Medical Device Market Surveillance | PMS, vigilance, market surveillance | tibbicihaz.pgd@titck.gov.tr |
Israel: AMAR and IRH Post-Market Obligations
Regulatory Framework
Israel's Medical Device Division of the Ministry of Health (AMAR), established under the Medical Equipment Law of 2012, requires post-market vigilance through the Israel Registration Holder (IRH).
IRH Post-Market Responsibilities
Under 2026 guidelines, the IRH must:
- Prepare periodic post-marketing reports for submission to AMAR
- Monitor global restrictions from other regulatory bodies that might affect the device's safety profile in Israel
- Report to the Minister of Health:
- Any significant deficiencies with the device that can impact patient health
- Any usage of the device that damaged a patient's health
- Any action taken by a foreign health authority
- Any notifications issued by the manufacturer
- Any new safety information published in scientific journals
Registration Renewal
- Registration validity: typically 5 years (2 years for implants), but cannot exceed validity of reference country's certificate
- Renewal applications must be submitted at least 4 months prior to expiration
- Renewal routes vary by class:
- Class I and Class A IVDs: Declaration Route
- Class IIa/IIb and Class B/C IVDs: Fast-Track Route
- Class III and Class D IVDs: Standard Route
- High-risk devices and IVDs must include a post-market report in their renewal submission
Selecting an Independent IRH
Using a distributor as IRH is legally possible but strategically risky — it ties registration to a commercial partner. If the manufacturer wishes to switch distributors, they may face a "hostage" situation with their license. An independent IRH allows distributor changes without affecting market approval. The IRH must hold ISO 9001 certification and have the capacity to fully support device registration and post-market compliance operations.
Egypt: EDA Vigilance and Post-Market Requirements
Regulatory Authority
The Egyptian Drug Authority (EDA) issued updated procedures in February 2026 to facilitate the registration and renewal of medical devices, including enhanced post-market requirements.
Post-Market Obligations
Under EDA's framework, the authorized representative (ERH — Egyptian Responsible Holder) must:
- Maintain a pharmacovigilance system for medical devices
- Submit periodic safety reports
- Report adverse events within defined timelines
- Manage product recalls and field safety corrective actions
- Maintain complaint handling procedures
- Keep the EDA informed of any safety-related changes to the device
February 2026 Simplification Measures
In February 2026, EDA introduced measures to streamline:
- Registration and renewal procedures for medical devices
- Evaluation criteria for devices in pharmaceutical dosage forms
- Digital submission processes for PMS reports
These changes aim to reduce administrative burden while maintaining safety oversight, particularly for the growing $4.37 billion Egyptian medical device market.
Comparative PMS Summary Across MENA
| Requirement | Saudi Arabia | UAE | Turkey | Israel | Egypt |
|---|---|---|---|---|---|
| Death/serious injury reporting | 2–10 days | 10 days | EU-aligned | Prompt via IRH | Defined timelines |
| Other incidents | 30 days | 30 days | EU-aligned | Via IRH | Defined timelines |
| Public health threat | 2 days | 48 hours | EU-aligned | Prompt via IRH | Defined timelines |
| PSUR requirement | Class C & D | Class III & IV (biennial) | EU-aligned | Periodic reports | Periodic reports |
| Change notification (significant) | 10 days | New approval | EU-aligned | Via IRH | Required |
| Change notification (non-significant) | 30 days | Notification | EU-aligned | Via IRH | Required |
| Renewal lead time | 90 days before expiry | 3–6 months | Per EU timeline | 4 months before expiry | Before expiry |
| Shortage notification | Not specified | Not specified | 6 months advance | Via IRH | Not specified |
| Record retention | 10 years (15 for implants) | Per EDE requirements | EU-aligned | Per AMAR requirements | Per EDA requirements |
Building a Unified MENA PMS Strategy
Centralized PMS Hub
For manufacturers operating across multiple MENA markets, a centralized PMS function is essential. This hub should:
- Collect and aggregate safety data from all MENA markets in a single database
- Route reports to the correct authority within country-specific timelines (the difference between Saudi Arabia's 2-day and UAE's 48-hour requirement for public health threats requires precise process design)
- Generate country-specific PSURs using the same underlying data but formatted for each authority's requirements
- Manage change notifications across all markets simultaneously
- Track renewal deadlines for each country and trigger preparation workflows
Economic Operator Oversight
Each MENA country assigns specific PMS responsibilities to different economic operators:
- Manufacturers: Ultimate responsibility for PMS data collection, analysis, and reporting
- Authorized Representatives / IRH / ERH: Local point of contact for regulatory authorities, responsible for ensuring reports reach authorities on time
- Importers and Distributors: Must report issues they become aware of and maintain distribution records
- Healthcare Providers: Must report adverse events observed in clinical practice
Manufacturers must contractually define these responsibilities with each local partner and maintain oversight through regular compliance audits.
Technology and Process Recommendations
- Implement a global safety database that can generate country-specific reports in the correct formats and track submission deadlines
- Establish local language capability for complaint handling and adverse event investigation — reports in Saudi Arabia, UAE, Egypt, and Turkey require local language elements
- Create a regulatory intelligence monitoring function to track evolving PMS requirements across all MENA markets — 2026 has seen significant updates in all five countries covered in this guide
- Build proactive signal detection into your MENA PMS program — authorities in the region increasingly expect manufacturers to identify emerging safety trends before they become mandatory reports
- Document everything: Saudi Arabia requires documented proof of user notification within 5 days of FSCA; Israel requires IRH monitoring of global restrictions; Turkey requires six-month advance notice of supply disruptions
Key Takeaways
Saudi Arabia's MDS-REQ 11 is the most detailed PMS framework in MENA with specific timelines for every stage of adverse event reporting (2/10/30 days), investigation closure (15/30/60 days), FSCA notification (2 days), and user notification (5 days).
UAE EDE mandates biennial PSURs for Class III/IV devices, with GVP-aligned timelines (70 days for ≤12-month intervals, 90 days for >12-month intervals). Renewal starts 3–6 months before expiry.
Turkey's 6-month shortage notification is unique in the region — manufacturers must forecast and report anticipated supply disruptions well in advance, with specific provisions for EU-established manufacturers versus local importers.
Israel requires IRH monitoring of global restrictions — the Israel Registration Holder must actively track regulatory actions worldwide and report any that affect the device's safety profile in Israel, making the choice of IRH critically important.
Egypt's February 2026 simplification measures streamline registration and renewal while maintaining safety oversight for Africa's second-largest medical device market ($4.37 billion).
Record retention in Saudi Arabia is 10 years (15 for implants) — among the longest in the region and requiring robust document management systems.